Certara (NASDAQ:CERT) Updates FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.350-0.410 for the period, compared to the consensus earnings per share estimate of 0.360. The company issued revenue guidance of $395.0 million-$405.0 million, compared to the consensus revenue estimate of $398.9 million.

Certara Stock Up 8.9%

Certara stock opened at $6.36 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The company’s 50-day moving average is $5.58 and its 200-day moving average is $6.90. The firm has a market capitalization of $989.39 million, a PE ratio of -63.60 and a beta of 1.49. Certara has a fifty-two week low of $4.45 and a fifty-two week high of $13.88.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. During the same period last year, the firm earned $0.14 EPS. Certara’s quarterly revenue was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Sell-side analysts anticipate that Certara will post 0.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on CERT shares. Stephens reduced their target price on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Barclays lowered their price target on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Robert W. Baird cut their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. Finally, KeyCorp decreased their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.85.

Institutional Trading of Certara

A number of hedge funds have recently bought and sold shares of CERT. Northwestern Mutual Wealth Management Co. raised its stake in shares of Certara by 2,733.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after acquiring an additional 2,870 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after buying an additional 4,930 shares during the period. Canada Pension Plan Investment Board purchased a new stake in Certara in the second quarter worth about $83,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Certara during the 4th quarter worth approximately $92,000. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.